Cargando…

Redox Regulating Enzymes and Connected MicroRNA Regulators Have Prognostic Value in Classical Hodgkin Lymphomas

There are no previous studies assessing the microRNAs that regulate antioxidant enzymes in Hodgkin lymphomas (HLs). We determined the mRNA levels of redox regulating enzymes peroxiredoxins (PRDXs) I–III, manganese superoxide dismutase (MnSOD), nuclear factor erythroid-derived 2-like 2 (Nrf2), and Ke...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karihtala, Peeter, Porvari, Katja, Soini, Ylermi, Haapasaari, Kirsi-Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362709/ https://www.ncbi.nlm.nih.gov/pubmed/28377796 http://dx.doi.org/10.1155/2017/2696071

Ejemplares similares

Oxidative stress and redox state-regulating enzymes have prognostic relevance in diffuse large B-cell lymphoma
por: Peroja, Pekka, et al.
Publicado: (2012)

The Role of Redox-Regulating Enzymes in Inoperable Breast Cancers Treated with Neoadjuvant Chemotherapy
por: Roininen, Nelli, et al.
Publicado: (2017)

Keap1 expression has independent prognostic value in pancreatic adenocarcinomas
por: Isohookana, Joel, et al.
Publicado: (2015)

High-level cytoplasmic claudin 3 expression is an independent predictor of poor survival in triple-negative breast cancer
por: Jääskeläinen, Anniina, et al.
Publicado: (2018)

NRF1 and NRF2 mRNA and Protein Expression Decrease Early during Melanoma Carcinogenesis: An Insight into Survival and MicroRNAs
por: Hämäläinen, Mari, et al.
Publicado: (2019)

Comparison of the mutational profiles of neuroendocrine breast tumours, invasive ductal carcinomas and pancreatic neuroendocrine carcinomas
por: Karihtala, Peeter, et al.
Publicado: (2022)

Reactive Oxygen Species-Mediated Mechanisms of Action of Targeted Cancer Therapy
por: Teppo, Hanna-Riikka, et al.
Publicado: (2017)

Nuclear factor erythroid 2-related factors 1 and 2 are able to define the worst prognosis group among high-risk diffuse large B cell lymphomas treated with R-CHOEP
por: Kari, Esa, et al.
Publicado: (2019)

Oxidative stress and counteracting mechanisms in hormone receptor positive, triple-negative and basal-like breast carcinomas
por: Karihtala, Peeter, et al.
Publicado: (2011)

Mutational signatures and their association with survival and gene expression in urological carcinomas
por: Karihtala, Peeter, et al.
Publicado: (2023)

Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP
por: Peroja, Pekka, et al.
Publicado: (2018)

Integrin alpha 10, CD44, PTEN, cadherin-11 and lactoferrin expressions are potential biomarkers for selecting patients in need of central nervous system prophylaxis in diffuse large B-cell lymphoma
por: Lemma, Siria A, et al.
Publicado: (2017)

NRF3 Decreases during Melanoma Carcinogenesis and Is an Independent Prognostic Marker in Melanoma
por: Immonen, Anni, et al.
Publicado: (2022)

Antithrombin III is probably not a suitable biomarker for diagnosis of primary central nervous system lymphoma
por: Kuusisto, Milla Elvi Linnea, et al.
Publicado: (2015)

T026: Characterization of cancer-associated fibroblasts in classical Hodgkin lymphoma
por: Karihtala, Kristiina, et al.
Publicado: (2022)

Primary neuroendocrine breast carcinomas are associated with poor local control despite favourable biological profile: a retrospective clinical study
por: Roininen, Nelli, et al.
Publicado: (2017)

Impact of central nervous system (CNS) prophylaxis on the incidence of CNS relapse in patients with high-risk diffuse large B cell/follicular grade 3B lymphoma
por: Kuitunen, Hanne, et al.
Publicado: (2020)

Prognostic Impact of Tumor-Associated Macrophages on Survival Is Checkpoint Dependent in Classical Hodgkin Lymphoma
por: Karihtala, Kristiina, et al.
Publicado: (2020)

Checkpoint protein expression in the tumor microenvironment defines the outcome of classical Hodgkin lymphoma patients
por: Karihtala, Kristiina, et al.
Publicado: (2022)

MicroRNA signature in classical Hodgkin lymphoma
por: Paczkowska, Julia, et al.
Publicado: (2021)

Genetics of classical Hodgkin Lymphoma
por: Schiavoni, Gianluca, et al.
Publicado: (2018)

Composite follicular lymphoma and classic Hodgkin lymphoma
por: Kim, Han-Na, et al.
Publicado: (2022)

The molecular mechanisms of classic Hodgkin's lymphoma.
por: Felberbaum, Rachael S.
Publicado: (2005)

Immunological Deregulation in Classic Hodgkin Lymphoma
por: Romano, Alessandra, et al.
Publicado: (2014)

Controversies in the Treatment of Classical Hodgkin Lymphoma
por: Eichenauer, Dennis A., et al.
Publicado: (2018)

The Grey Zones of Classic Hodgkin Lymphoma
por: Bosch-Schips, Jan, et al.
Publicado: (2022)

The real risk of secondary non-Hodgkin lymphoma following classical Hodgkin lymphoma
por: Dogan, Ahmet
Publicado: (2022)

Tackling the dysregulated immune-checkpoints in classical Hodgkin lymphoma: bidirectional regulations between the microenvironment and Hodgkin/Reed-Sternberg cells
por: Cellini, Alessandro, et al.
Publicado: (2023)

Bob-1 is expressed in classic Hodgkin lymphoma
por: Abd El All, Howayda S
Publicado: (2007)

Resources-Stratified Guidelines for Classical Hodgkin Lymphoma
por: Relecom, Allan, et al.
Publicado: (2020)

Bone marrow involvement by classic Hodgkin lymphoma
por: Barouqa, Mohammad, et al.
Publicado: (2022)

Aberrant synaptophysin expression in classic Hodgkin lymphoma
por: Im, Soyoung, et al.
Publicado: (2022)

Current directions in the treatment of classical Hodgkin lymphoma
por: Keller, Frank G., et al.
Publicado: (2023)

CAR-T Cell Therapy for Classical Hodgkin Lymphoma
por: Katsin, Mikalai, et al.
Publicado: (2023)

The impact of classic Hodgkin lymphoma on informal caregivers: results from the CONNECT cross-sectional survey
por: Flora, Darcy R., et al.
Publicado: (2023)

Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility
por: Sud, Amit, et al.
Publicado: (2017)

Biology and Clinical Applicability of Plasma Thymus and Activation-Regulated Chemokine (TARC) in Classical Hodgkin Lymphoma
por: Zijtregtop, Eline A. M., et al.
Publicado: (2021)

Genomic analyses of microdissected Hodgkin and Reed-Sternberg cells: mutations in epigenetic regulators and p53 are frequent in refractory classic Hodgkin lymphoma
por: Mata, Elena, et al.
Publicado: (2019)

Treatment outcomes in classic Hodgkin lymphoma: 5‐year update from the Brazilian Hodgkin Lymphoma Registry
por: Biasoli, Irene, et al.
Publicado: (2023)

Claudins in lung diseases
por: Soini, Ylermi
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_h21u50a6j5gh73urjdebj783hq